UBS Initiates Buy on Charles River Laboratories (CRL) Amid Positive CRO Sector Outlook

gurufocus.com · 2026-09-30

On September 30, 2026, UBS launched coverage of Charles River Laboratories International Inc (NYSE: CRL) with a Buy rating and a price target of $357, citing a

TickrTrends take: UBS's initiation of a Buy rating on Charles River Laboratories arrives during a period when TickrTrends' valuation analysis indicates the stock is trading at Overvalued levels, creating a divergence between analyst sentiment and current pricing metrics. For valuation-conscious investors in the Healthcare sector, this disconnect warrants close monitoring of whether upcoming earnings or sector developments might justify the current valuation multiples or whether mean reversion could occur. The positive CRO sector outlook cited by UBS suggests fundamentals may strengthen, but the overvalued designation suggests any upside would need to be substantial to absorb existing premium valuations.

Read the full story at gurufocus.com →